partnering with pfizer 6
DESCRIPTION
TRANSCRIPT
Partnering with Pfizer
6th Annual Rice AllianceLife Science Technology Venture Forum
Dr B J Bormann, Vice PresidentStrategic Alliances
June 6th, 2007
Partnering with Pfizer
6th Annual Rice AllianceLife Science Technology Venture Forum
Dr B J Bormann, Vice PresidentStrategic Alliances
June 6th, 2007
� Jury Duty, last person in the pool of 200, interviewed at 5 pm� Selected as an alternate for jury, ‘medical condition’ civil trial� Closing arguments, juror was ill� Chosen as replacement� Deliberations
– I was alone in my opinion, needed to convince fellow jurors– Do you remember “Twelve Angry Men?”
� All took > 2 weeks
� Cancelled my presence but not my presentation last year� You saw my slides presented by Dr. Ajay Gautam, a Rice
alum.
� I have mostly new slides for you this year
� Jury Duty, last person in the pool of 200, interviewed at 5 pm� Selected as an alternate for jury, ‘medical condition’ civil trial� Closing arguments, juror was ill� Chosen as replacement� Deliberations
– I was alone in my opinion, needed to convince fellow jurors– Do you remember “Twelve Angry Men?”
� All took > 2 weeks
� Cancelled my presence but not my presentation last year� You saw my slides presented by Dr. Ajay Gautam, a Rice
alum.
� I have mostly new slides for you this year
Last YearLast Year
“Pfizer has had a long history of great innovations, but it recognizes that no single
company has a monopoly on good ideas. To build on and
complement its strengths, Pfizer actively seeks out alliances.”
William Steere, Former CEO of Pfizer1999
Agenda Today:�A wee bit of Pfizer Propaganda�A Flash review of challenges to the pharmaceutical business�The evolution of Pfizer by Alliances
�Biologics�Diagnostics
�New Paradigms�Scripps�The Pfizer Incubator
Agenda Today:�A wee bit of Pfizer Propaganda�A Flash review of challenges to the pharmaceutical business�The evolution of Pfizer by Alliances
�Biologics�Diagnostics
�New Paradigms�Scripps�The Pfizer Incubator
Pfizer HistoryPfizer History
�������������� ���������������������������������������������������������������� ��������������������������������������������������
�������������� !������� "�# ���$%��������&����'�!��(���)����������������
�������������� !������� "�# ���$%��������&����'�!��(���)����������������
Charles PfizerCharles Pfizer
Charles Charles ErhartErhart
Pfizer ProductsPfizer Products
2007 Key Products by Therapeutic Area
AriceptCabaserDilantinGeodon/ZeldoxLyricaMirapexNeurontinRebifRelpaxXanax XRZoloft/Zustrel
AriceptCabaserDilantinGeodon/ZeldoxLyricaMirapexNeurontinRebifRelpaxXanax XRZoloft/Zustrel
DiflucanSulperazonUnasynVfendViraceptZithromaxZyvox
DiflucanSulperazonUnasynVfendViraceptZithromaxZyvox
GenotropinSomavertGenotropinSomavert
CamptosarEllence/PharmorubicinAromasinSutent
CamptosarEllence/PharmorubicinAromasinSutent
Spiriva/DaxasZyrtec/Zyrtec DSpiriva/DaxasZyrtec/Zyrtec D
XalatanMacugenXalatanMacugen
Accupril/AccureticGlucotrol/Glucotrol XLInspraLipitorNorvasc/IstinProcardia/Procardia XLTikosynExubera
Accupril/AccureticGlucotrol/Glucotrol XLInspraLipitorNorvasc/IstinProcardia/Procardia XLTikosynExubera
Depo-ProveraDepo-Provera
Cardura/Cardura XLDetrolViagra
Cardura/Cardura XLDetrolViagra
Celebrex/CelebraBextraDynastat
Celebrex/CelebraBextraDynastatSource: Pfizer 2006 Year-End Corporate Earnings Release
Central Nervous System
Endocrine
OncologyInfectious Disease
Allergy/Respiratory Pain/Inflammation
Women’s Health
Urology
Cardiovascular/Metabolic
Ophthalmology
Phase 2
Preclinical &Phase 1
Phase 3In Registration
63632727
121244
102102 333388
1111
R&D Results – Pipeline Growth
July 2003:106 NMEsJuly 2003:106 NMEs
154 New Molecular Entities154 New Molecular Entities
6
Candidates in Advanced DevelopmentCandidates in Advanced Development
Exubera Diabetes- APPROVED
ParecoxibParecoxib Acute PainAcute Pain
Sildenafil PAH Pulmonary Arterial Hypertension
Torcetrapib/Atorvastatin Atherosclerosis-FAILED
Varenicline Smoking Cessation-APPROVED
Asenapine Schizophrenia
SU-11248 GIST, Renal Cancer-APPROVEDEdotecarin Colorectal Cancer
Zithromax/Chloroquine Malaria
UK-427,857 HIV
Metabolic Diseases
Inflammation & Immunology
Allergy & Respiratory
Cardiovascular
Neurosciences
Oncology
Infectious Diseases
� Efficacy Studies Complete
� Long Term Pulmonary Safety Studies Continuing
� Efficacy Studies Complete
� Long Term Pulmonary Safety Studies Continuing
ExuberaDiabetesExuberaDiabetes
Varenicline – Alpha 4-Beta 2 Partial AgonistSmoking CessationVarenicline – Alpha 4-Beta 2 Partial AgonistSmoking Cessation
� Orally Effective Nicotinic Partial Agonist
� Reduces Nicotine Cravings
� 1.3 Billion Smokers Worldwide
� Average 50% Continuous Quit Rate After 12 Week Treatment Compared to 12% With Placebo
�� Orally Effective Nicotinic Orally Effective Nicotinic Partial AgonistPartial Agonist
�� Reduces Nicotine CravingsReduces Nicotine Cravings
�� 1.3 Billion Smokers 1.3 Billion Smokers WorldwideWorldwide
�� Average 50% Continuous Average 50% Continuous Quit Rate After 12 Week Quit Rate After 12 Week Treatment Compared to Treatment Compared to 12% With Placebo12% With Placebo
UK-427,857 HIV Entry InhibitorUK-427,857 HIV Entry Inhibitor
HIV Cell Entry InhibitionHIV Cell Entry Inhibition
� First-in-Class
� Selective, Reversible Binding to the CCR-5 Receptor
� Excellent Pharmacokinetics and Selectivity
� Potent In Vitro Activity Against Resistant Strains
� No Drug-Drug Interactions
�� FirstFirst--inin--ClassClass
�� Selective, Reversible Binding to Selective, Reversible Binding to the CCRthe CCR--5 Receptor5 Receptor
�� Excellent Pharmacokinetics and Excellent Pharmacokinetics and SelectivitySelectivity
�� Potent In Vitro Activity Against Potent In Vitro Activity Against Resistant StrainsResistant Strains
�� No DrugNo Drug--Drug InteractionsDrug Interactions
SU-11,248Cancer
� Multi-Targeted VEGFR Kinase Inhibitor
� Remarkable Efficacy Seen in Gastrointestinal Stromal Tumor and Renal Cell Carcinoma Cancers
�� MultiMulti--Targeted VEGFR Targeted VEGFR Kinase InhibitorKinase Inhibitor
�� Remarkable Efficacy Remarkable Efficacy Seen in Gastrointestinal Seen in Gastrointestinal Stromal Tumor and Stromal Tumor and Renal Cell Carcinoma Renal Cell Carcinoma CancersCancers
Inhibits Tumor VascularizationInhibits Tumor VascularizationInhibits Tumor Vascularization
Disrupts Tumor SurvivalDisrupts Tumor SurvivalDisrupts Tumor Survival
CTLA-4: TicilimumabOncologyCTLA-4: TicilimumabOncology
� Cyctotoxic T Lymphocyte-associated Antigen-4 Antibody
� CTLA-4 Blockade with CP-675,206 May Break Peripheral Immunological Tolerance and Induce Anti-tumor Activity
� Currently Conducting Phase III Study Using Multiple Doses
�� Cyctotoxic T LymphocyteCyctotoxic T Lymphocyte--associated Antigenassociated Antigen--4 4 AntibodyAntibody
�� CTLACTLA--4 Blockade with CP4 Blockade with CP--675,206 May Break Peripheral 675,206 May Break Peripheral Immunological Tolerance and Immunological Tolerance and Induce AntiInduce Anti--tumor Activitytumor Activity
�� Currently Conducting Phase Currently Conducting Phase III Study Using Multiple DosesIII Study Using Multiple Doses
�*+,��������"�������������+-,�*�� �����*+,��������"�������������+-,�*�� ����
La Jolla, CA, U.S.A.Rinat Labs
La Jolla, CA, U.S.A.Rinat Labs
New London andGroton, CT, U.S.A.New London and
Groton, CT, U.S.A.
St. Louis, MO, U.S.A.St. Louis,
MO, U.S.A.
SingaporeSingapore
Cambridge,MA, U.S.A.
Cambridge,MA, U.S.A.
Sandwich,ENGLANDSandwich,ENGLAND
Toronto, CanadaToronto, Canada
Sydney, AustraliaSydney, Australia
Seoul, KoreaSeoul, Korea
Shanghai, ChinaShanghai, China
R&D Therapeutic AreasR&D Therapeutic Areas
�������������� ���� ������������ ����
����� ����� � ������
�������� � ����� �������
������� � ������������ ����
������������ � ��
� ���� ��������� ������
� ����� ��� � �� � ��!� ���
"� ���� "��� ������
# ���������� � $������
%��������� %��� �� ����
* Pfizer has exited ‘research’ in Dermatology and GI* Pfizer has exited ‘research’ in Dermatology and GI
Pharmaceutical Industry Challenges
Pharmaceutical Industry Challenges
High Attrition Rate in Drug DevelopmentHigh Attrition Rate in Drug Development
.//�,����&����"((�������.//�,����&����"((�������
� 0���������
�� 0�0�����������������
High Risk Process12-15 years, ~$900MM/candidate
High Risk Process12-15 years, ~$900MM/candidate
DiscoveryDiscovery Exploratory DevelopmentExploratory Development
IdeaIdea DrugDrug11 11 -- 15 Years15 Years
Full DevelopmentFull Development
Phase I Phase II Phase III
00 151555 1010
Preclinical Pharmacology
Preclinical Safety
Thousands ofCompounds Screened
Clinical Pharmacology& Safety
~250~250
~5~5
Generic SubstitutionGeneric Substitution
� August 2, 2001 - Barr Laboratories cleared to ship generic version of Lilly’s Prozac
� By September 2001, 80% of Lilly’s Prozac sales were taken by Barr Laboratories substitute product
� August 2, 2001 - Barr Laboratories cleared to ship generic version of Lilly’s Prozac
� By September 2001, 80% of Lilly’s Prozac sales were taken by Barr Laboratories substitute product
Key products representing >$50 billion are set to lose exclusivity in 2007
- Decision Resources, May 2003
Shrinking Market ExclusivityShrinking Market Exclusivity
InderalInderal -- 19651965
TagametTagamet -- 19771977
CapotenCapoten -- 19801980
SeldaneSeldane -- 19851985
AZT - 1987
MevacorMevacor -- 19871987
Prozac Prozac -- 19881988
DiflucanDiflucan -- 19901990
RecombinateRecombinate -- 19921992
Celebrex Celebrex -- 19991999
0 1 2 3 4 5 0 1 2 3 4 5 6 7 8 9 106 7 8 9 10
Years of Exclusivity for Innovative DrugYears of Exclusivity for Innovative Drug
Lopressor Lopressor -- 19781978
Zantac Zantac -- 19831983
VasotecVasotec -- 19851985
Hismanal Hismanal –– 19891989
VidexVidex –– 19911991
PravacholPravachol –– 19911991
Zoloft Zoloft –– 19921992
SporonoxSporonox –– 19921992
KogenateKogenate –– 19921992
VioxxVioxx–– 19991999
Innovative Drug /Innovative Drug /Year IntroducedYear Introduced
22ndnd GenerationGenerationDrug/YearDrug/Year
Productivity ChallengeProductivity Challenge
%�����+-,�)�&���# ����12��������3%�����+-,�)�&���# ����12��������3
$0$0
$5$5
$10$10
$15$15
$20$20
$25$25
1970
1970
1975
1975
1980
1980
1985
1985
1990
1990
1995
1995
2000
2000
# NCEs# NCEs60604040202000
Source: 2004 PhRMA Annual Survey, 2003/2004 PAREXEL’S Pharmaceutical Industry SourcebookSource: 2004 PhRMA Annual Survey, 2003/2004 PAREXEL’S Pharmaceutical Industry Sourcebook
$30$30
$35$35
2003
2003
Adding Value:
Pfizer Strategic Alliances
Adding Value:
Pfizer Strategic Alliances
SA supports a fully Integrated R & D ProcessSA supports a fully Integrated R & D Process
Target Identification
Toxicology
In Silico Modeling
Compound Screening
Lead Optimization
Human Trials
Target Validation
Computational Chemistry
Animal Studies
�
�
�� �
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
� �
�
�
��
�
StrategicAlliancesStrategicAlliances
� Our alliance investments are:
� Integrated and aligned with our global strategies, initiatives and internal investments
� Address opportunities and gaps to create competitive advantage
� Enable the low-cost evaluation of novel opportunities� Provide access to novel technologies with the potential to
change the current R&D paradigm� Managed with respect to the science, business, legal and IP
issues� Assessed and monitored with appropriate metrics
� Our alliance investments are:
� Integrated and aligned with our global strategies, initiatives and internal investments
� Address opportunities and gaps to create competitive advantage
� Enable the low-cost evaluation of novel opportunities� Provide access to novel technologies with the potential to
change the current R&D paradigm� Managed with respect to the science, business, legal and IP
issues� Assessed and monitored with appropriate metrics
Adding value: the SA visionAdding value: the SA vision
“Cradle to grave Alliance Management”“Cradle to grave Alliance Management”
Change in growth
rate
mAbs
Recombinant proteins
Cell therapy
Gene
Prophylactic vaccines
Size indicates relative potential market size*Size indicates relative potential market size*Therapeutic
vaccines
Change in growth
rate
mAbs
Recombinant proteins
Antisense
Cell therapy
Gene therapy
Prophylactic vaccines
Relative level of platform validation (time)
Size indicates relative potential market size*Size indicates relative potential market size*Therapeutic
vaccines
Therapeutic BiologicsRelative Maturity of Biologics Market SegmentsTherapeutic BiologicsRelative Maturity of Biologics Market Segments
Insulin & erythropoietinsare market leadersInsulin & erythropoietinmarket leaders
$32.6BOver 100 products currently in developmentOver 100 products currently in development
$7.3B
0
5
10
15
20
25
30
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
From a single program in 1996 to over 25 programs today, Pfizer continues to increase its
Biologics Portfolio.
Growth of Pfizer’s Biologics PortfolioGrowth of Pfizer’s Biologics Portfolio
MCSF mAbMCSF mAb
MAdCAM mAbMAdCAM mAb
IGF1R mAbIGF1R mAb
PEGPEG--hGHhGH
ETCETC--642642
TLR CPG 7909TLR CPG 7909
T2T2--TrpRSTrpRS
CD40 mAbCD40 mAb
CTLA4 mAbCTLA4 mAb
ETCETC--588588 ETCETC--216216
(interferon beta-1a) (dalteparin sodium injection)(pegvisomant for injection) human insulin powder
Expanding the Scope of R&DFuture Biologics PowerhouseExpanding the Scope of R&DFuture Biologics Powerhouse
4�25���������������4�25���������������0//6������'����!�����1�7(�����30//6������'����!�����1�7(�����3
NY 7/31/2006
Expanding Oncology Portfolio: CP-675,206Expanding Oncology Portfolio: CP-675,206
����$�%8"��# "
Many “Firsts” for Pfizer Oncology
Melanoma MonoclonalAntibody
Immuno-therapeutics
First ImmunotherapeuticNovel MOA that enhances immune
system (“removes the brake”)Broad applicability for all tumor types Option to lead in Tumor Immunology
First Fully-Human mAbFocus on cutting edge science
Sales of biologics estimated at 31% of cancer market in 2009
vs 18% in 2003*
Biotherapeutics and Macromolecules
Development
Candidates
Manufacturing
ODN TLR9 angonist
Candidate
Biologics manufacturing
ODN manufacturing
Process
Development
Discovery /
Lead Generation
Transgenic Mouse fully human mAbplatform
Transgenic Mouse fully human mAbplatform
Spiegelmer(Modified Aptamer) Obesity Candidate and platform
antisense platform
Phage display fully human mAbplatform
Cell line engineering using ZFP nucleases
Pegylation & InhalationTechnologies
High efficiency mammalian expression system
Rapid generation of high expression cell lines
RNAi for wet AMD
Diagnostics Will Be Enablers of Rx SalesExample SituationsDiagnostics Will Be Enablers of Rx SalesExample Situations
Example driver
Overall Pfizer Impact
All TAs have identified areas of diagnostics needAll TAs have identified areas of diagnostics need
Situation where Dx adds value Example Impact
Uptake and Compliance
Diagnostic that identifies presymptomatic individuals eligible for preventive/ disease-modifying treatment
Alzheimer’s Disease, test + disease-modifying drug
Potential to grow market by 10M+ individuals; multiple billion dollar value
Market ShareDiagnostic that indicates best therapy for individuals
HIV, resistance profile, Maraviroc
Rapid ramp-up and share increase; multiple hundred million dollar value
Market SizeDiagnostics that identifies subpopulation eligible for treatment
Breast cancer, HercepTest, Herceptin
Fragments market, but increases price and share within fragment
External Diagnostics Landscape – EvolvingExternal Diagnostics Landscape – Evolving
� The diagnostics market has total revenues of $70-75B(1) is growing at ~7% pa and has margins varying by technology segment from 5% to 30%
� Electronics companies are merging the traditional technology segments (in vivo and in vitro), pursuing higher margin services and IT revenues from clinical institutional customers
� Most large pharma companies (Merck, GSK, Bristol-Myers Squibb) have elected for selective diagnostics licensing deals focusing on support for specific portfolio assets
� Diagnostics will grow in importance in healthcare decision-making over the long term, driven by expansion in evidence-based treatment, shifts to early testing and screening and demand for personalized medicine
� The diagnostics market has total revenues of $70-75B(1) is growing at ~7% pa and has margins varying by technology segment from 5% to 30%
� Electronics companies are merging the traditional technology segments (in vivo and in vitro), pursuing higher margin services and IT revenues from clinical institutional customers
� Most large pharma companies (Merck, GSK, Bristol-Myers Squibb) have elected for selective diagnostics licensing deals focusing on support for specific portfolio assets
� Diagnostics will grow in importance in healthcare decision-making over the long term, driven by expansion in evidence-based treatment, shifts to early testing and screening and demand for personalized medicine
(1) Including in vitro, in vivo direct and in vivo IT and Services
Business Dynamics for DiagnosticsBusiness Dynamics for Diagnostics
• Revenues smaller (~$55B(1) relative to pharmaceutical ~$600B), margins lower (10-20%), and growth equivalent (~7%).
Short-term diagnostics business
Acquisitionchallenges in in vivo
Acquisition challenges in in vitro
Key short-termtrends
Landscape ofactivity
Long-term diagnostics business
Long-term Impact Of Dx On Rx
• Attractive segments fragmented; in select transactions studied, market paid $5-7B, for base revenues of ~$0.8B and revenue growth of ~$0.2B per annum
• Three key players; theoretically pay $15-25B (Philips Medical Systems) to $55-75B (GE Healthcare), for base revenues of $9B (PMS) to $15B (GEHC) and revenue growth of $0.4B (PMS) to $2.7B (GEHC) per annum
• No indication of a large improvement in diagnostics business
• Integrated Rx-Dx businesses have struggled to synergize• Companies entering or expanding are doing so for different reasons
• Critical longer-term enablers of pharmaceutical revenues
�����
����
• More attractive as diagnostics expected to grow considerably in importance as drivers of healthcare decisions
Key Trends: Limited Short-Term Change
Pricing under pressure
• Prices historically very low, continued downward pressure by payors• Reimbursement challenge: labs often have to absorb test costs• But, several trend-breakers may be emerging, such as in molecular diagnostics
(e.g., Genomic Health’s Oncotype Dx)
Increasing regulatory hurdles
Capabilities being commoditized
• Many segments already highly commoditized (e.g., clinical chemistry)• Higher margin segments seeing downward pressure with new entries
Long-term growing importance in healthcare
decision-making
• Human Genome Project, SNP Consortium and Hap Map are synergistic with diagnostic development
• Diagnostics likely to be much more important in driving healthcare decisions
• Variable regulatory path (PMA, 510(k), class I ASR, home-brew)( at FDA discretion• Recent examples indicate intent of FDA to increase hurdles
- Refusal to allow Roche AmpliChip as ASR in 2003- Draft proposal to regulate Multivariate Index Assays, February 2007
Limited IP protection• Few areas of real exclusivity• Many ways to resolve a particular Dx problem allows circumvention of IP
Expansion in Evidence-based treatment
• Market increasingly demands evidence-based treatment selection that can be provided by diagnostics
• Theranostics now standard for HIV, increasing for HBV and HCV
• Potential to grow Rx market for many indications• E.g., Biomarker and diagnostic development to identify pre-symptomatic Alzheimer’s Disease
Shift to early testing and screening
Demand for Personalized Medicine
• Diagnostics to identify molecular basis of disease important during both R&D and commercial
• Huge potential impact across many diseases currently defined by clusters of symptoms and tests
Longer-Term, Diagnostics Growing in ImportanceLonger-Term, Diagnostics Growing in Importance
� Aureon Labs
� Avid Radiopharmaceuticals
� Genizon
� Genomic Health
� ICardiac
� Monogram
� M2S
� Perlegen
� Virtual Scopics
� Aureon Labs
� Avid Radiopharmaceuticals
� Genizon
� Genomic Health
� ICardiac
� Monogram
� M2S
� Perlegen
� Virtual Scopics
� Cogstate
� Epidauros
� General Electric
� Oxford biosensors
� Source Mdx
Current and Past “Investments” in Diagnostics
Equity Non-Equity
New ParadigmsNew Paradigms
Recent DealsRecent Deals
� Scripps� An infusion of new ideas, fresh science
� The Pfizer Incubator� Nurturing ‘solutions’ to Pfizer ‘technology gaps or
problem statements
� Scripps� An infusion of new ideas, fresh science
� The Pfizer Incubator� Nurturing ‘solutions’ to Pfizer ‘technology gaps or
problem statements
The Collaborative Research Program Between The Scripps Research Institute and Pfizer
The Collaborative Research Program Between The Scripps Research Institute and Pfizer
General Provisions of CollaborationGeneral Provisions of Collaboration
� 5 year term
� Governed by Steering Committee (SC) with equal representation from Scripps and Pfizer
� Areas of Defined Collaboration� 2 Target Biology Projects/Year� 10 Screen Configurations/Year (Drug Pfinder)� Biological Libraries – creation/screening
� First option to license up to 47% of inventions
� First option to fund any corporate-sponsored research
� Collaboration in other fields as approved by SC
� Sabbatical Opportunities
� 5 year term
� Governed by Steering Committee (SC) with equal representation from Scripps and Pfizer
� Areas of Defined Collaboration� 2 Target Biology Projects/Year� 10 Screen Configurations/Year (Drug Pfinder)� Biological Libraries – creation/screening
� First option to license up to 47% of inventions
� First option to fund any corporate-sponsored research
� Collaboration in other fields as approved by SC
� Sabbatical Opportunities
The Pfizer Incubator Business ModelThe Pfizer Incubator Business Model
Value to Pfizer• Early access to enabling technologies• Flow of products at various stages at lower cost• Agility in exploring new technologies & processes
Value to Entrepreneurs• Easy hassle-free start-up, focus on science• Strategic advice from the ultimate customer• Opportunity for faster payoff
TPI Board needs• to ensure nimble
decision making
• to have flexibility to pursue different legal structures
• to reconcile compliance with certain Pfizer policies and procedures in the context of TPI and incubated entities
Founder(s)IP, know-how
NewCoExecutes Research
Plan
TPI$$*, facilities,
operational support
TPI acquires exclusive rights• Value negotiated or by third party• TPI cannot acquire only a portion
of company - cherry pick (in most situations)
• Milestones, royalties can provide long-term reward for founders
Spin out• TPI may acquire non-exclusive
license• NewCo can raise funding from
external investors or be acquired• NewCo moves out of incubator• TPI may remain a stakeholder
(no Board seat)
• Agreed upon objectives, research plan
• 2 year funding, 6 month milestones
• Plan and milestones can be changed if approved by TPI Board
• Equity share negotiated at start
• TPI has a Board seat • TPI reserves an option to
buy out founders based on negotiated or 3rd party valuation
Project initiation / Entity Creation
Incubation Exit Scenarios
TPI LLC
Entrepreneurs-In-Residence (EIRs)
Open innovation manager
TPI Head
TPI Organization, facilities and service modelTPI Organization, facilities and service model
TPI LLC is an umbrella organization under which multiple incubators at various locations can be run: scalable structure
TPI Board
Expert advisors
Investment budget for LJ incubator: $10M/y
Operating budget for 2007: $2.5M
LJ Incubator
Company 1
Company 2
Company 3
Incubator Head
Employees/contractors
Concierge
Service model
IncubatorEntity
ConciergeServices
IT
EHS
FacilitiesServices
Supplies/Logistics
Security
Pod
11st Floor
� 26,600 sq. ft.
� 5 dedicated labs (divisible into 8)
� Office space to support 70+ people
� Glass wash & central services
� Shipping / receiving location
� Least invasive renovation
� Shell space provides future flexibility
CB7
Thanks for Listening!!Thanks for Listening!!
� Pfizer is a superb partner� If an opportunity fits within our strategy, we are
nimble� We negotiate deals appropriate for the opportunity� We focus on the science� We manage the Alliances with purpose and for
success
� Any Questions?
� Pfizer is a superb partner� If an opportunity fits within our strategy, we are
nimble� We negotiate deals appropriate for the opportunity� We focus on the science� We manage the Alliances with purpose and for
success
� Any Questions?